Page last updated: 2024-08-25

zoledronic acid and Fracture, Pathologic

zoledronic acid has been researched along with Fracture, Pathologic in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (32.79)	29.6817
2010's	38 (62.30)	24.3611
2020's	3 (4.92)	2.80

Authors

Authors	Studies
Bryan, JN; Ehling, TJ; Flesner, BK; Keys, DA; Lattimer, JC; Maitz, CA; Moore, M; Norquest, CJ	1
Cruz, C; Malamud, S; Miyashita, H	1
Ebata, T; Ishiwata, T; Iwasawa, S; Saito, G; Takiguchi, Y; Tatsumi, K; Yoshino, I	1
Biggin, A; Munns, CF	1
Lüftner, D; Niepel, D; Steger, GG	1
Cheng, P; Durie, B; García-Sanz, R; Krejčí, M; Laribi, K; Legieć, W; Raje, N; Roodman, GD; Shimizu, K; Terpos, E; Warner, D; Willenbacher, W; Zhu, L	1
Arai, Y; Kawakami, S; Kitayama, S; Otsuka, Y; Shirotake, S; Yano, A	1
Harada, H; Hosaka, S; Katagiri, H; Murata, H; Niwakawa, M; Takahashi, M; Wasa, J	1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T	1
Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK	1
Gartrell, BA; Saad, F	1
Ngarmukos, S; Tanavalee, A; Tantavisut, S; Thanakit, V; Wangroongsub, Y; Wilairatana, V	1
Paniagua, L; Roldan, CJ	1
Beer, TM; Graff, JN	1
Coleman, R; Efstathiou, E; Fizazi, K; Gartrell, BA; Logothetis, CJ; Saad, F; Sartor, O; Smith, MR; Sonpavde, G	1
Balakumaran, A; Body, JJ; Braun, A; Brown, J; Cleeland, C; Damyanov, D; Egerdie, B; Fallowfield, L; Marx, G; Palazzo, FS; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R; Zhou, Y	1
Bismuth, H; Brin, YS; Coughlin, R; Heler, Z; Kish, BJ; Nyska, M; Palmanovich, E; Rotman, P; Zehavi, T	1
Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M	1
Chang, B; Du, SX; Hu, QX; Li, XD; Lin, FX; Xie, D; Yu, GY; Zheng, GZ	1
Blanco, R; Sánchez, A	1
Chew, H; Dakhil, SR; Gradishar, WJ; Haley, BB; Harker, WG; Hortobagyi, GN; Lipton, A; Mohanlal, R; Sauter, N; Van Poznak, C; Zheng, M	1
Agrillo, A; Corsi, A; Riminucci, M; Ungari, C	1
Traut, V	1
Martens, MG; Shaw, H	1
Hagino, H; Hashimoto, J; Katagiri, H; Okano, T	1
Okazaki, R	1
Bilezikian, JP	1
Grasko, JM; Herrmann, RP; Vasikaran, SD	1
Fakler, O; Gutwald, R; Liebehenschel, N; Sauerbier, S; Schmelzeisen, R; Wagner, K; Wongchuensoontorn, C	1
Das, RR; Marwaha, RK; Panigrahi, I	1
Beresniak, A; Bisot-Locard, S; Bresse, X; Cortet, B; Fardellone, P; Legrand, E; Vigneron, AM	1
Black, DM; Boonen, S; Colón-Emeric, CS; Eastell, R; Eriksen, EF; Haentjens, P; Lyles, KW; Magaziner, JS; Mesenbrink, P	1
Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H; Takano, M; Yano, M	1
Abrahamsen, B; Eiken, PA	1
Arduino, PG; Broccoletti, R; Dalmasso, P; Mozzati, M; Scoletta, M	1
López-Carrizosa, MC; Pérez, AR; Samper-Ots, PM	1
Eastham, J; Saad, F	1
Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP	1
Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P	1
Dimopoulos, MA; Terpos, E	1
Gupta, SK; Reddy, SV	1
Henk, HJ; Kaura, S; Perez, JR; Teitelbaum, A	1
Beaujeux, R; Boujan, F; Boyer, P; Cebula, H; Froelich, S	1
Birkholz, K; Gruenwald, V; Kindler, M; May, C; Miller, K; Ruebel, A; Schultze-Seemann, W; Schulze, M; Stenzl, A; Strauss, A; Tunn, UW; Wirth, MP; Zantl, N	1
Morgans, AK; Smith, MR	1
Barney, RB; Biskupiak, JE; Brandt, P; Gaffney, DK; Namjoshi, M; Nickman, NA; Young, J	1
Gomez-Veiga, F; Martinez-Breijo, S; Morote, J; Planas, J; Ponce-Reixa, J	1
Huang, B; Li, CL; Liang, R; Pan, LH; Qian, W; Zheng, WW; Zhong, JH; Zhu, M	1
Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M	1
Biskobing, DM; Downs, R; Novy, AM	1
Cook, R; Major, PP	1
Reid, IR	1
Lin, SH; Logothetis, C; Tu, SM	1
Saad, F	2
Khuri, F; Saba, N	1
Gogia, N; Kumar, R; Mahapatra, M; Malik, M; Pillai, LS; Puri, T; Sharma, DN	1
Kouvaris, C; Mouzopoulos, D; Mouzopoulos, G; Stamatakos, M; Tzurbakis, M	1
Nitschmann, S; Ringe, JD	1
Langdahl, BL; Rejnmark, L	1

Reviews

18 review(s) available for zoledronic acid and Fracture, Pathologic

Article	Year
Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta. Current osteoporosis reports, 2017, Volume: 15, Issue:5 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Orthopedic Procedures; Osteogenesis Imperfecta; Pamidronate; Physical Therapy Modalities; Quality of Life; Zoledronic Acid	2017
Therapeutic approaches for protecting bone health in patients with breast cancer. Breast (Edinburgh, Scotland), 2018, Volume: 37 Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Practice Guidelines as Topic; Spinal Cord Compression; Zoledronic Acid	2018
Pathologic fracture in patients with metastatic prostate cancer. Current opinion in urology, 2014, Volume: 24, Issue:6 Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid	2014
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:6 Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid	2015
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European urology, 2015, Volume: 68, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Radioisotopes; Radium; Zoledronic Acid	2015
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. European journal of cancer care, 2017, Volume: 26, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Orthopedic Procedures; Prostatic Neoplasms; Radiotherapy; Spinal Cord Compression; Zoledronic Acid	2017
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection]. Clinical calcium, 2008, Volume: 18, Issue:8 Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Osteoporosis; Zoledronic Acid	2008
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. Clinical calcium, 2009, Volume: 19, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid	2009
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. The American journal of medicine, 2009, Volume: 122, Issue:2 Suppl Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid	2009
[Bone and Men's Health. Bisphosphonate therapy for prostate cancer]. Clinical calcium, 2010, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2010
Bone-targeted agents: preventing skeletal complications in prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid	2012
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas urologicas espanolas, 2013, Volume: 37, Issue:5 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Double-Blind Method; Forecasting; Fractures, Spontaneous; Humans; Imidazoles; Male; Models, Biological; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Practice Guidelines as Topic; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid	2013
Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials. Pain medicine (Malden, Mass.), 2013, Volume: 14, Issue:2 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Musculoskeletal Pain; Pain Measurement; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2013
Novel therapeutic options for osteoporosis. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid	2002
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1 Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2002
Bisphosphonates: new indications and methods of administration. Current opinion in rheumatology, 2003, Volume: 15, Issue:4 Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid	2003
Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clinical prostate cancer, 2002, Volume: 1, Issue:3 Topics: Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid	2002
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses. Oncology, 2005, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Multicenter Studies as Topic; Nerve Compression Syndromes; Pain; Spinal Cord Compression; United States; Zoledronic Acid	2005

Trials

8 trial(s) available for zoledronic acid and Fracture, Pathologic

Article	Year
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate. Breast cancer research and treatment, 2020, Volume: 182, Issue:2 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Disease-Free Survival; Female; Fractures, Spontaneous; Humans; Middle Aged; Risk Assessment; Risk Factors; Spinal Cord Compression; Zoledronic Acid	2020
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet. Oncology, 2018, Volume: 19, Issue:3 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid	2018
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid	2014
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:3 Topics: Analgesics; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Zoledronic Acid	2016
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid	2017
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology, 2010, Volume: 76, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Pain; Pain Measurement; Prostatic Neoplasms; Spinal Cord Compression; Survival Rate; Zoledronic Acid	2010
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. The Lancet. Oncology, 2011, Volume: 12, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; United Kingdom; Zoledronic Acid	2011
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. The Canadian journal of urology, 2012, Volume: 19, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Spinal Cord Compression; Tomography, X-Ray Computed; Zoledronic Acid	2012

Other Studies

35 other study(ies) available for zoledronic acid and Fracture, Pathologic

Article	Year
Fracture rate and time to fracture in dogs with appendicular osteosarcoma receiving finely fractionated compared to coarsely fractionated radiation therapy: A single institution study. Veterinary medicine and science, 2022, Volume: 8, Issue:3 Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Fractures, Spontaneous; Humans; Osteosarcoma; Retrospective Studies; Zoledronic Acid	2022
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Spinal Cord Compression; Zoledronic Acid	2021
Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:8 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Fractures, Spontaneous; Humans; Male; Middle Aged; Multivariate Analysis; Propensity Score; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid	2018
Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis. International journal of clinical oncology, 2018, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Chemoradiotherapy; Female; Fractures, Spontaneous; Humans; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Spinal Cord Compression; Sunitinib; Survival Rate; Treatment Outcome; Zoledronic Acid	2018
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid	2013
Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid. Clinics in orthopedic surgery, 2014, Volume: 6, Issue:3 Topics: Acetabulum; Aged; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Hip Prosthesis; Humans; Imidazoles; Osteoarthritis, Hip; Periprosthetic Fractures; Prosthesis Failure; Reoperation; Zoledronic Acid	2014
Complications of new medications. The western journal of emergency medicine, 2015, Volume: 16, Issue:1 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Mandibular Fractures; Zoledronic Acid	2015
Spontaneous Bilateral Femoral Fractures After High-Dose Zoledronic Acid. Orthopedics, 2015, Volume: 38, Issue:11 Topics: Aged; Bone Density Conservation Agents; Diaphyses; Diphosphonates; Female; Femoral Fractures; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid	2015
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. The oncologist, 2016, Volume: 21, Issue:4 Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Pamidronate; Proportional Hazards Models; Retrospective Studies; Risk Factors; Zoledronic Acid	2016
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:3 Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fractures, Spontaneous; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Radiography; Zoledronic Acid	2017
Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2017, Volume: 75, Issue:8 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Diphosphonates; Fatal Outcome; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Mandible; Mandibular Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid	2017
[Zoledronic acid for preventing fractures]. Der Internist, 2008, Volume: 49, Issue:8 Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Survival Analysis; Treatment Outcome; Zoledronic Acid	2008
Maximizing effectiveness of bisphosphonate therapy for osteoporosis. Southern medical journal, 2008, Volume: 101, Issue:8 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid	2008
Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:3 Topics: Bone Density Conservation Agents; Cross Infection; Diphosphonates; Escherichia coli Infections; Fatal Outcome; Femoral Fractures; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Recurrence; Zoledronic Acid	2009
Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:6 Topics: Administration, Oral; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Mandibular Fractures; Middle Aged; Osteonecrosis; Palliative Care; Tooth Extraction; Zoledronic Acid	2009
Zolendronate in osteogenesis imperfecta. Journal of pediatric endocrinology & metabolism : JPEM, 2009, Volume: 22, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Infant; Infant, Newborn; Lumbar Vertebrae; Male; Osteogenesis Imperfecta; Radiography; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2009
Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Models, Econometric; Osteoporosis, Postmenopausal; Patient Care; Randomized Controlled Trials as Topic; Zoledronic Acid	2010
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. Journal of the American Geriatrics Society, 2010, Volume: 58, Issue:2 Topics: Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Femoral Neck Fractures; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Medication Adherence; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid	2010
[Assessment and treatment of osteoporotic hip fractures]. Ugeskrift for laeger, 2010, Mar-01, Volume: 172, Issue:9 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Hip Fractures; Humans; Imidazoles; Life Style; Middle Aged; Osteoporosis; Practice Patterns, Physicians'; Risk Factors; Surveys and Questionnaires; Zoledronic Acid	2010
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 110, Issue:1 Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic Disease; Clindamycin; Cohort Studies; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Jaw Diseases; Male; Oral Fistula; Osteonecrosis; Pamidronate; Penicillins; Prospective Studies; Remission Induction; Risk Factors; Smoking; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid	2010
Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:8 Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Prognosis; Prospective Studies; Statistics, Nonparametric; Zoledronic Acid	2010
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4 Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid	2011
Zoledronic acid for all patients with newly diagnosed multiple myeloma? The Lancet. Oncology, 2011, Volume: 12, Issue:8 Topics: Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Zoledronic Acid	2011
Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singapore medical journal, 2012, Volume: 53, Issue:3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Follow-Up Studies; Fracture Fixation, Intramedullary; Fracture Healing; Fractures, Spontaneous; Humans; Imidazoles; Male; Neoplasm Staging; Orchiectomy; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Radiography; Risk Assessment; Zoledronic Acid	2012
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. American journal of hematology, 2012, Volume: 87, Issue:5 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Utilization; Female; Fractures, Spontaneous; Humans; Imidazoles; Incidence; Infusions, Intravenous; International Classification of Diseases; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Osteolysis; Retrospective Studies; Treatment Outcome; United States; Zoledronic Acid	2012
[Giant cell tumor of the C2 colonized by an aneurismal bone cyst. Report of case]. Neuro-Chirurgie, 2012, Volume: 58, Issue:6 Topics: Accidents, Home; Adult; Bone Cysts, Aneurysmal; Bone Density Conservation Agents; Bone Plates; Cervical Vertebrae; Diphosphonates; Embolization, Therapeutic; Fracture Fixation, Internal; Fractures, Spontaneous; Giant Cell Tumors; Humans; Imidazoles; Ligation; Magnetic Resonance Imaging; Male; Odontoid Process; Spinal Cord Compression; Spinal Fractures; Spinal Neoplasms; Spinal Stenosis; Tomography, X-Ray Computed; Torticollis; Vertebral Artery; Zoledronic Acid	2012
Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Musculoskeletal Pain; Palliative Care; Retrospective Studies; Treatment Outcome; Young Adult; Zoledronic Acid	2013
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid	2013
[Bisphosphonates in bone metastases. Fewer fractures, less pain]. MMW Fortschritte der Medizin, 2002, Sep-26, Volume: 144, Issue:39 Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Pain; Pamidronate; Zoledronic Acid	2002
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Bisphosphonates in prostate cancer: where are we and where should we go? Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Paraplegia due to extramedullary hematopoiesis in thalassemia treated successfully with radiation therapy. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adult; beta-Thalassemia; Blood Transfusion; Calcium; Cobalt Radioisotopes; Contraindications; Decompression, Surgical; Diphosphonates; Epidural Space; Folic Acid; Fractures, Spontaneous; Hematopoiesis, Extramedullary; Humans; Imidazoles; Male; Osteoporosis; Paraplegia; Radioisotope Teletherapy; Spinal Cord Compression; Zoledronic Acid	2007
Spontaneous bilateral subcapital hip fracture due to multiple myeloma: an 18-month follow-up. European journal of cancer care, 2007, Volume: 16, Issue:5 Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femoral Neck Fractures; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Radiography; Zoledronic Acid	2007
[Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)]. Der Internist, 2008, Volume: 49, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Osteoporosis; Randomized Controlled Trials as Topic; Secondary Prevention; Zoledronic Acid	2008
[Osteoporosis--new therapeutic possibilities. The Danish Bone Society]. Ugeskrift for laeger, 2008, Mar-17, Volume: 170, Issue:12 Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2008